Genmab — Juni 2017
-
Citi's nyeste reference omkring cd38's rolle http://www.sciencedirect.com/science/article/pii/S0092867417304294 - hvis tiden er knap kan man blot læse "Discussion". God pinse til alle !
-
Fra Celgenes Q1 CC: Michael Pehl: An important near term growth driver in the U.S. will be the expected (min fremhævelse) FDA approval of POMALYST in combination with daratumumab for relapsed refractory myeloma by June of this year. https://seekingalpha.com/article/4066320-celgene-celg-q1-2017-results-earnings-call-transcript?part=single
-
Hold nu op Solsen. Vi kan læse herfra og til mandag aften. Det er squ for langhåret efter 3 glas rødvin
-
Tidspunkterne for Genmabs præsentationer ligger på - http://files.shareholder.com/downloads/AMDA-KPIBN/4448022645x0x938217/26f665a4-b920-4cbc-adcd-0054c322da34/i03_ASCO_200417_uk.pdf
-
Super. Tak Bulder.
-
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind